Provectus Biopharmaceuticals Inc (PVCT) Financial Statements (2026 and earlier)

Company Profile

Business Address 800 S. GAY STREET
KNOXVILLE, TN 37929
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)
Annual | Quarterly

3/31/2026
MRQ
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments251307772268397
Cash and cash equivalent251307772268397
Restricted cash and investments  1829501,4102,424 
Receivables   005 
Prepaid expense216223 467330323
Other current assets 71236    
Other undisclosed current assets2927338  4
Total current assets:5689771,3651,8993,442424
Noncurrent Assets
Operating lease, right-of-use asset127257211740121
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization3512213245
Intangible asset, including goodwill, after accumulated amortization      (11,715)
Intangible asset, excluding goodwill, after accumulated amortization      (11,715)
Other undisclosed noncurrent assets      11,715
Total noncurrent assets:130298413871166
TOTAL ASSETS:6981,0061,4492,0373,513589
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:3,9003,3004,9394,5293,3015,233
Interest and dividends payable✕✕✕✕✕112,775
Accounts payable7161,1071,6762,0941,287957
Accrued liabilities3,1612,2533,2632,4352,0021,501
Other undisclosed accounts payable and accrued liabilities22(59)    
Deferred revenue  3369531,511  
Debt2002001,0788641,26016,622
Due to related parties✕✕✕✕1,2032006,770
Other undisclosed current liabilities2,7973,1392,047852,9402,087
Total current liabilities:6,8976,9759,0178,1927,70130,712
Noncurrent Liabilities
Long-term debt and lease obligation 24    45
Long-term debt, excluding current maturities 24     
Liabilities, other than long-term debt79 2573  
Operating lease, liability79 2573 45
Other undisclosed noncurrent liabilities      (6)
Total noncurrent liabilities:103 2573 84
Total liabilities:7,0006,9759,0428,2667,70130,796
Equity
Equity, attributable to parent, including:(6,299)(5,959)(7,593)(6,229)(4,187)(30,206)
Common stock420420420419419399
Additional paid in capital256,180251,090244,715242,954241,440209,923
Accumulated other comprehensive loss(60)(61)(60)(36)(34)(34)
Accumulated deficit(262,854)(257,423)(252,690)(249,589)(246,034)(240,494)
Other undisclosed equity, attributable to parent1514232222 
Equity, attributable to noncontrolling interest(4)(10)    
Total equity:(6,303)(5,969)(7,593)(6,229)(4,187)(30,206)
TOTAL LIABILITIES AND EQUITY:6981,0061,4492,0373,513589

Income Statement (P&L) ($ in thousands)
Annual | Quarterly

3/31/2026
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Revenues336617558989  
Gross profit:336617558989  
Operating expenses(5,631)(5,150)(3,459)(4,417)(4,672)(4,964)
Operating loss:(5,295)(4,532)(2,901)(3,428)(4,672)(4,964)
Nonoperating expense (210)(230)(201)(127)(867)(1,714)
Interest and debt expense  (6) 63(1,748)
Other undisclosed loss from continuing operations before equity method investments, income taxes      
Loss from continuing operations before equity method investments, income taxes:(5,505)(4,762)(3,107)(3,555)(5,476)(8,426)
Other undisclosed income (loss) from continuing operations before income taxes(0) (19) (63)7,748
Loss from continuing operations before income taxes:(5,505)(4,762)(3,126)(3,555)(5,540)(678)
Income tax expense (benefit) 444(344)705(671)(736)(276)
Other undisclosed income from continuing operations      
Loss from continuing operations:(5,061)(5,106)(2,421)(4,225)(6,275)(953)
Loss before gain (loss) on sale of properties:✕✕✕✕✕(6,275)(953)
Other undisclosed net income (loss)(444)344    
Net loss:(5,505)(4,762)(2,421)(4,225)(6,275)(953)
Net income attributable to noncontrolling interest7430    
Other undisclosed net income (loss) attributable to parent   (680)671736(5,724)
Net loss available to common stockholders, diluted:(5,431)(4,733)(3,102)(3,555)(5,540)(6,678)

Comprehensive Income ($ in thousands)
Annual | Quarterly

3/31/2026
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Net loss:(5,505)(4,762)(2,421)(4,225)(6,275)(953)
Other comprehensive income (loss)1(1)(24)(1)(0)(10)
Comprehensive loss:(5,505)(4,763)(2,446)(4,227)(6,275)(963)
Comprehensive income, net of tax, attributable to noncontrolling interest7430    
Other undisclosed comprehensive income (loss), net of tax, attributable to parent  (30)(680)671736(5,724)
Comprehensive loss, net of tax, attributable to parent:(5,430)(4,763)(3,126)(3,556)(5,540)(6,688)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: